Show simple item record

dc.contributor.authorEyal, Nir
dc.contributor.authorLipsitch, Marc
dc.date.accessioned2020-10-07T13:13:24Z
dc.date.issued2020
dc.identifier.citationEyal, Nir, and Marc Lipsitch. Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure, 2020.en_US
dc.identifier.urihttps://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37365585*
dc.description.abstractA vaccine trial with a standard challenge design can be faster than standard phase III once it starts, but it requires a long prior process, in part, to grow and standardize challenge virus in the laboratory. This detracts somewhat from its overall promise for accelerated efficacy testing of SARS-CoV-2 vaccine candidates, and from the ability of developing countries and small companies to conduct it. We describe a challenge design that avoids this part of the long prior process. The new design has additional ethical, scientific, and feasibility strengths, compared to standard challenge designs and to standard phase III designs, and should be considered for future vaccine trials.en_US
dc.language.isoen_USen_US
dash.licenseLAA
dc.subjectCoronavirusen_US
dc.subjectVaccinesen_US
dc.subjectHuman Challenge Studiesen_US
dc.subjectRandomized Controlled Trialsen_US
dc.subjectResearch Designen_US
dc.subjectEthicsen_US
dc.titleTesting SARS-CoV-2 vaccine efficacy through deliberate natural viral exposureen_US
dc.typeJournal Articleen_US
dc.description.versionAuthor's Originalen_US
dash.depositing.authorLipsitch, Marc
dc.date.available2020-10-07T13:13:24Z
dash.affiliation.otherHarvard T.H. Chan School of Public Healthen_US
dash.contributor.affiliatedEyal, Nir
dash.contributor.affiliatedLipsitch, Marc


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record